Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?

Fong, Sharon Lie; Baart, Esther B.; Martini, Elena; Schipper, I.; Visser, Jenny A.; Themmen, Axel P. N.; Jong, Frank H. de; Fauser, Bart; Laven, Joop S.E.

doi:10.1016/s1472-6483(10)60480-4

Cited by 122 publications

(68 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several authors have found a significant positive correlation between AMH levels and oocyte quality [30][31][32] and embryo morphology [32]. However, this relationship has not been confirmed by others [33,34]. Moreover, in a recent study, no consistent correlation between AMH and embryo morphology, and most importantly embryo aneuploidy rate, was demonstrable [34].…”

Section: Discussionmentioning

confidence: 90%

Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

Kini

Morrell

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate the role of Anti-mullerian hormone (AMH) in predicting cumulative pregnancy outcome during in-vitro fertilization (IVF) treatment. Methods Serum AMH levels on day 6 of ovarian stimulation were taken from 180 women undergoing IVF with or without intracytoplasmic sperm injection (ICSI). The main outcome measures were ongoing pregnancy in the fresh cycle, cumulative ongoing pregnancy and ovarian response.Results There was a trend of higher median AMH levels in subjects achieving ongoing pregnancy in the fresh IVF cycle. The median AMH levels were significantly higher in subjects attaining ongoing pregnancy cumulatively and in subjects showing ovarian hyper-response in the stimulated cycle. Areas under the ROC curves were 0.606 and 0.792 for the prediction of cumulative ongoing pregnancy and ovarian hyper-response respectively. Conclusions Serum AMH concentration on day 6 of stimulation was significantly higher in subjects who achieved cumulative ongoing pregnancy in IVF compared to those who did not. Serum AMH is a reasonably good predictor of ovarian hyper-response.

show abstract

Section: Discussionmentioning

confidence: 90%

Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

Kini

Morrell

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Despite some differences in study design, our findings were consistent with previous work and lend further strength to the conclusion that there is no association between low AMH levels and fetal aneuploidy. In addition, a recent study explored the relationship between AMH levels and embryo quality [35]. Embryo quality was assessed by both an embryo morphology score and preimplantation genetic screening.…”

Section: Discussionmentioning

confidence: 99%

Maternal antimullerian hormone levels do not predict fetal aneuploidy

Plante

Beamon

Schmitt

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To determine if diminished ovarian reserve (measured by maternal antimullerian hormone (AMH) levels), is associated with fetal aneuploidy (determined by prenatal karyotype). Methods This case-control study included 213 women with singleton pregnancies who underwent both serum aneuploidy screening and invasive prenatal diagnosis. 18 patients carrying an aneuploid fetus served as cases and the remaining 195 women with a euploid fetus were controls. Serum AMH was measured using two assays: AMHbc (Beckman-Coulter) and AMHdsl (Diagnostic Systems Laboratories). Karyotypes were determined by chorionic villus sampling or amniocentesis. Results AMHbc levels did not differ between women with an aneuploid fetus and women with a euploid fetus (p= 0.46) and did not predict aneuploidy (ROC Area=0.57). Additionally, AMHbc values declined significantly with advancing gestational age. Conclusions Maternal AMH does not appear to be a marker of fetal aneuploidy in ongoing pregnancies. Contrary to previous reports, we found a significant decline in maternal AMH levels with advancing gestational age.

show abstract

“…Several studies found a significant positive correlation between AMH levels and the quality of oocytes (Hazout et al 2004, Ebner et al 2006, Silberstein et al 2006, Cupisti et al 2007, Fanchin et al 2007, Lekamge et al 2007) and embryo morphology (Silberstein et al 2006). However, this relationship has not been confirmed by other authors (Smeenk et al 2007, Lie Fong et al 2008a, and the predictive value of serum AMH on oocyte competence and embryo quality remains controversial (La Marca et al 2010).…”

Section: Amh and Assisted Reproductive Technologymentioning

confidence: 98%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?

Cited by 122 publications

References 27 publications

Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

Maternal antimullerian hormone levels do not predict fetal aneuploidy

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Contact Info

Product

Resources

About